APA

Conference Coverage: American Psychiatric Association’s (APA) Annual Meeting

May 13, 2024

The 2024 American Psychiatric Association’s Annual Meeting wrapped up on May 8, 2024. Below are selected highlights of the research presented at the meeting.

Case report describes suicidal ideation in semaglutide recipient

According to a poster presentation, GLP-1 receptor agonists may exacerbate symptoms in patients with psychiatric disorders. A 42-year-old female who exhibited suicidal ideations after initiating semaglutide was the subject of this case study. Researchers examined extant literature to attempt to identify the mechanism by which GLP-1 medications worsen psychiatric conditions and trigger suicidal ideation. Read more.

Single dose of MM-120 (Lysergide) appears effective and safe for GAD

Generalized anxiety disorder is among the most common psychiatric disorders. Despite this, there has been little progress in the development of effective and well-tolerated therapies. Authors reported on the safety and tolerability of 4 different doses of MM-120 (D-lysergic acid diethylamide D-tartrate) and found that a 100µg dose achieved the highest level of clinical activity compared with placebo at week 4, with clinical activity evident as early as day 2 after treatment. Read more.

Nomophobia or “no mobile phone phobia” and physicians

While smartphones have made communication easier, they can also incite feelings of discomfort, anxiety, or nervousness when the owner is out of contact with their mobile phone. Researchers conducted a global cross-sectional study on nomophobia, or “No Mobile Phone Phobia,” among health care professionals (HCPs) and found that 64.2%, 22.6%, and 15.6% of HCPs met the criteria for moderate, severe, and mild nomophobia, respectively. Read more.

Update on study of iclepertin use in patients with schizophrenia

In this poster presentation, investigators shared baseline data from the CONNEX-X extension study, an ongoing effort to collect additional safety data related to iclepertin treatment in patients with cognitive impairment associated with schizophrenia (CIAS). Iclepertin is a glycine transporter-1 inhibitor. Read more.

Investigating the use of stigmatizing language in clinical notes

Patients from racial and ethnic minority backgrounds and those with obesity and substance use disorders have been impacted by conscious and unconscious biases among healthcare professionals in various ways, including through language used in clinical notes in EHRs. Using a list of terms classified as stigmatizing by the National Institute of Drug Abuse, researchers developed a natural language processing algorithm to extract those terms from clinical notes. Patients in the age group 18 to 32 years had a lower incidence of stigmatizing language (SL) in their notes compared with other age groups. Patients with a higher incidence of SL tended to be older, female, Black and/or Hispanic. Read more.